Pharmacological Preconditioning of Mesenchymal Stem Cells with Trimetazidine (1-[2,3,4-Trimethoxybenzyl]piperazine) Protects Hypoxic Cells against Oxidative Stress and Enhances Recovery of Myocardial Function in Infarcted Heart through Bcl-2 Expression
- 13 February 2009
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 329 (2), 543-550
- https://doi.org/10.1124/jpet.109.150839
Abstract
Stem cell transplantation is a possible therapeutic option to repair ischemic damage to the heart. However, it is faced with a number of challenges including the survival of the transplanted cells in the ischemic region. The present study was designed to use stem cells preconditioned with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine; TMZ), a widely used anti-ischemic drug for treating angina in cardiac patients, to increase the rate of their survival after transplantation. Bone marrow-derived rat mesenchymal stem cells (MSCs) were subjected to a simulated host tissue environment by culturing them under hypoxia (2% O2) and using hydrogen peroxide (H2O2) to induce oxidative stress. MSCs were preconditioned with 10 μM TMZ for 6 h followed by treatment with 100 μM H2O2 for 1 h and characterized for their cellular viability and metabolic activity. The preconditioned cells showed a significant protection against H2O2-induced loss of cellular viability, membrane damage, and oxygen metabolism accompanied by a significant increase in HIF-1α, survivin, phosphorylated Akt (pAkt), and Bcl-2 protein levels and Bcl-2 gene expression. The therapeutic efficacy of the TMZ-preconditioned MSCs was evaluated in an in vivo rat model of myocardial infarction induced by permanent ligation of left anterior descending coronary artery. A significant increase in the recovery of myocardial function and up-regulation of pAkt and Bcl-2 levels were observed in hearts transplanted with TMZ-preconditioned cells. This study clearly demonstrated the potential benefits of pharmacological preconditioning of MSCs with TMZ for stem cell therapy for repairing myocardial ischemic damage.Keywords
This publication has 41 references indexed in Scilit:
- Sulfaphenazole Protects Heart Against Ischemia–Reperfusion Injury and Cardiac Dysfunction by Overexpression of iNOS, Leading to Enhancement of Nitric Oxide Bioavailability and Tissue OxygenationAntioxidants and Redox Signaling, 2009
- Cardioprotection by HO-4038, a novel verapamil derivative, targeted against ischemia and reperfusion-mediated acute myocardial infarctionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Strategies to promote donor cell survival: Combining preconditioning approach with stem cell transplantationJournal of Molecular and Cellular Cardiology, 2008
- Hypoxic Preconditioning Results in Increased Motility and Improved Therapeutic Potential of Human Mesenchymal Stem CellsThe International Journal of Cell Cloning, 2008
- Hypoxic preconditioning attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cellsActa Pharmacologica Sinica, 2008
- Trimetazidine Protective Effect Against Ischemia-Induced Susceptibility to Ventricular Fibrillation in PigsCardiovascular Drugs and Therapy, 2007
- Skeletal myoblasts transplanted in the ischemic myocardium enhance in situ oxygenation and recovery of contractile functionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Labeling of skeletal myoblasts with a novel oxygen-sensing spin probe for noninvasive monitoring of in situ oxygenation and cell therapy in heartAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Effects of chronic trimetazidine treatment on myocardial preconditioning in anesthetized ratsFundamental & Clinical Pharmacology, 2006
- Cytokine Preconditioning Promotes Codifferentiation of Human Fetal Liver CD133 + Stem Cells Into Angiomyogenic TissueCirculation, 2005